Subscribe to RSS
DOI: 10.1055/s-0031-1281047
Diagnosis and Management of von Willebrand Disease: A Developing Country Perspective
Publication History
Publication Date:
18 November 2011 (online)
![](https://www.thieme-connect.de/media/sth/201105/lookinside/thumbnails/10.1055-s-0031-1281047-1.jpg)
ABSTRACT
Special challenges exist in the management of patients with von Willebrand disease (VWD) because of limitations in diagnostic facilities and therapeutic options. However, even within these limitations, it is possible to establish comprehensive services for this condition. Our data show that among 202 patients with VWD, 107 were type 3, 62 were type 1, and the others different categories of type 2. Basic tests such as bleeding time and activated partial thromboplastin time with factor (F)VIII coagulant are able to diagnose most of those with severe disease. We have been able to adapt the specific tests such as von Willebrand factor (VWF) ristocetin cofactor and VWF antigen from the tedious batched manual methods to cost-effective automated methods on advanced coagulometers. Discriminatory tests such as VWF collagen binding, VWF:FVIIIB, ristocetin-induced platelet agglutination (RIPA) are done in batches. Therapeutic options and for the treatment of bleeding include desmopressin, cryoprecipitate, and intermediate purity VWF-containing clotting factor concentrates. Tranexamic acid is also widely used as well as hormonal therapy for menorrhagia. We have also shown that modest doses of intermediate purity FVIII (Koate DVI; Talecris Biotherapeutics, Raleigh, NC, USA) at 35 IU/kg preoperatively and 10 to 20 IU/kg after that are sufficient for surgical hemostasis in these patients.
KEYWORDS
von Willebrand disease - developing countries - diagnosis - therapy
REFERENCES
- 1 Nichols WL, Hultin MB, James AH et al.. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008; 14 (2) 171-232
- 2 Srivastava A. von Willebrand disease in the developing world. Semin Hematol. 2005; 42 (1) 36-41
- 3 Srivastava A, Rodeghiero F. Epidemiology of von Willebrand disease in developing countries. Semin Thromb Hemost. 2005; 31 (5) 569-576
- 4 Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia. 2010; 16 (1) 20-32
- 5 Ivy AC, Nelson D, Bucher G. The standardization of certain factors in the cutaneous venostasis bleeding time technique. J Lab Clin Med. 1941; 26 1812-1822
- 6 Koster T, Caekebeke-Peerlinck KM, Briet E. A randomized and blinded comparison of the sensitivity and the reproducibility of the Ivy and Simplate II bleeding time techniques. Am J Clin Pathol. 1989; 92 (3) 315-320
- 7 Favaloro EJ. Toward a new paradigm for the identification and functional characterization of von Willebrand disease. Semin Thromb Hemost. 2009; 35 (1) 60-75
- 8 Lattuada A, Preda L, Sacchi E, Gallo L, Federici AB, Rossi E. A rapid assay for ristocetin cofactor activity using an automated coagulometer (ACL 9000). Blood Coagul Fibrinolysis. 2004; 15 (6) 505-511
- 9 Sakthivel MSM, Nair SC, Srivastava A et al.. Ristocetin cofactor (VWF:RCo) assay—a comparison of a rapid automated method on ACL 10000 coagulometer and conventional aggregometry. J Thromb Haemost. 2005; 3 (Suppl 1) P0868
- 10 Lawrie AS, Mackie IJ, Machin SJ, Peyvandi F. Evaluation of an automated platelet-based assay of ristocetin cofactor activity. Haemophilia. 2011; 17 (2) 252-256
- 11 Favaloro EJ. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease. Blood Rev. 1999; 13 (4) 185-204
- 12 Veyradier A, Fressinaud E, Sigaud M, Wolf M, Meyer D. A new automated method for von Willebrand factor antigen measurement using latex particles. Thromb Haemost. 1999; 81 (2) 320-321
- 13 Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res. 1986; 43 (3) 303-311
- 14 Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med. 1980; 302 (19) 1047-1051
- 15 Scott JP, Montgomery RR. The rapid differentiation of type IIb von Willebrand's disease from platelet-type (pseudo-) von Willebrand's disease by the “neutral” monoclonal antibody binding assay. Am J Clin Pathol. 1991; 96 (6) 723-728
- 16 Casonato A, Pontara E, Zerbinati P, Zucchetto A, Girolami A. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications. Am J Clin Pathol. 1998; 109 (3) 347-352
- 17 Nishino M, Girma J-P, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood. 1989; 74 (5) 1591-1599
- 18 Federici AB, Canciani MT, Forza I, Cozzi G. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease—single center comparison of four different assays. Thromb Haemost. 2000; 84 (6) 1127-1128
- 19 Eikenboom J, Van Marion V, Putter H et al.. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost. 2006; 4 (4) 774-782
- 20 Sadler JE, Budde U, Eikenboom JC Working Party on von Willebrand Disease Classification et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006; 4 (10) 2103-2114
- 21 Castaman G, Eikenboom JCJ, Bertina RM, Rodeghiero F. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost. 1999; 82 (3) 1065-1070
- 22 Federici AB, Castaman G, Thompson A, Berntorp E. von Willebrand's disease: clinical management. Haemophilia. 2006; 12 (Suppl 3) 152-158
- 23 Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost. 2003; 1 (4) 682-689
- 24 Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis. 2005; 16 (Suppl 1) S17-S21
- 25 Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. 1997; 90 (7) 2515-2521
- 26 Lethagen S, Harris AS, Sjörin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost. 1987; 58 (4) 1033-1036
- 27 Kirtava A, Crudder S, Dilley A, Lally C, Evatt B. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia. 2004; 10 (2) 158-161
- 28 Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia. 2004; 10 (3) 243-249
- 29 Srivastava A, Mathews V, Bhurani D, Baidya S, Chandy M. Successful surgical hemostasis in patients with von Willebrand disease following infusion of KoateDVI. Thromb Haemost. 2002; 87 (3) 541-543
- 30 Viswabandya A, Mathews V, George B et al.. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI. Haemophilia. 2008; 14 (4) 763-767
- 31 Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM. HAEMATE P Surgical Study Group . von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost. 2007; 5 (7) 1420-1430
- 32 Shortt J, Dunkley S, Rickard K, Baker R, Street A. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures. Haemophilia. 2007; 13 (2) 144-148
- 33 Michiels JJ, Berneman Z, van der Planken M, Schroyens W, Budde U, van Vliet HHDM. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII/von Willebrand concentrate (Haemate-P). Blood Coagul Fibrinolysis. 2004; 15 323-330
- 34 Nossent AY, Dai L, Rosendaal FR, Vos HL, Eikenboom JC. Beta 2 adrenergic receptor polymorphisms: association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis. J Thromb Haemost. 2005; 3 (2) 405-407
Alok SrivastavaM.D. F.R.A.C.P. F.R.C.P.A. F.R.C.P.
Department of Haematology
Christian Medical College, Vellore 632004, India
Email: aloks@cmcvellore.ac.in